- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07632157
MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation (MAGNETIC-AF)
MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation (MAGNETIC-AF)
The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).
Visão geral do estudo
Status
Intervenção / Tratamento
Descrição detalhada
Intravenous magnesium has become a commonly utilized agent in the treatment of cardiac arrhythmias as an adjunct therapy to rate and rhythm control medications, such as its use in atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR). Though its benefit in the treatment of AFF RVR has been well documented, a consensus on the optimal dosing of magnesium has yet to be achieved. Only one randomized, controlled, double-blinded study has investigated the optimal dosing of magnesium. The purpose of this prospective, randomized, double-blinded study is to further evaluate the safety and efficacy of varying doses of intravenous magnesium in the treatment of atrial fibrillation or atrial flutter with rapid ventricular response. This study will use flat-dose intravenous metoprolol for rate control to minimize confounders. Additionally, this study will not require a resulted magnesium level prior to treatment in order to avoid delays in patient care.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Marc McDowell, PharmD
- Número de telefone: (708) 684-1078
- E-mail: marc.mcdowell@aah.org
Estude backup de contato
- Nome: Thomas Szwajnos
- E-mail: Thomas.Szwajnos@aah.org
Locais de estudo
-
-
Illinois
-
Oak Lawn, Illinois, Estados Unidos, 60453
- Recrutamento
- Advocate Christ Medical Center Emergency Department (ACMC ED)
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age > 18 years or older
- Able to provide informed consent
- Primary diagnosis atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR) greater than or equal to 120 beats per minute
- Metoprolol as rate control agent
- English speaking
Exclusion Criteria:
- Hemodynamically unstable patients (SBP <90, MAP <65)
- Impaired consciousness
- Acute heart failure exacerbation based on clinical diagnosis, physician exam, bedside echo, and/or additional imaging
- Patient in AFF RVR that is highly suspected to be a compensatory mechanism for an alternative clinical diagnosis
- Rhythms other than atrial fibrillation, such as sick sinus syndrome or wide-complex ventricular response
- Acute myocardial infarction
- Contraindications to magnesium sulfate (including myasthenia gravis)
- Allergy or sensitivity to any study drugs
- Previously enrolled in this trial during a different patient encounter
- Withdrew from study
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Experimental Arm One, Magnesium Sulfate 2g followed by metoprolol 5 mg
Study drug (Magnesium Sulfate 2 gram/50ml 0.9% NaCl) will be administered over a time interval of 15 minutes. Immediately after study drug administration, intravenous metoprolol 5 mg will be administered as an IV push over 2 minutes. Additional doses of metoprolol 5 mg as an IV push over 1 minute permissible, however additional doses of study drug will not be administered. Emergency Medicine physician may provide additional doses of intravenous metoprolol every 5 minutes based on clinical necessity. |
Magnesium Sulfate 2g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Outros nomes:
|
|
Experimental: Experimental Arm Two, Magnesium Sulfate 4g followed by metoprolol
Study drug (Magnesium Sulfate 4 gram/50ml 0.9% NaCl) will be administered over a time interval of 15 minutes. Immediately after study drug administration, intravenous metoprolol 5 mg will be administered as an IV push over 2 minutes. Additional doses of metoprolol 5 mg as an IV push over 1 minute permissible, however additional doses of study drug will not be administered. Emergency Medicine physician may provide additional doses of intravenous metoprolol every 5 minutes based on clinical necessity. |
Magnesium Sulfate 4g for the treatment of atrial fibrillation or atrial flutter with rapid ventricular response (AFF RVR)
Outros nomes:
|
|
Comparador de Placebo: Control Arm, normal saline followed by metoprolol
50ml 0.9% NaCl will be administered over a time interval of 15 minutes. Intravenous metoprolol 5 mg will be immediately administered as an IV push over 2 minutes. Additional doses of metoprolol 5 mg as an IV push over 1 minute permissible, however additional doses of saline will not be administered. Emergency Medicine physician may provide additional doses of intravenous metoprolol every 5 minutes based on clinical necessity. |
The control group will receive a bolus of normal saline of the same volume and infused over 15 minutes.
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Ventricular rate control
Prazo: Within the first 2 hours of intravenous magnesium administration
|
Assessing ventricular rate control within the first 2 hours of intravenous magnesium administration as defined as a ventricular rate of < 120 beats per minute. |
Within the first 2 hours of intravenous magnesium administration
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Mean change in heart rate
Prazo: up to 24 hours after magnesium infusion
|
Mean change in heart rate after the administration of magnesium sulfate |
up to 24 hours after magnesium infusion
|
|
Incidence of hypotension
Prazo: At 1 and 2 hours after magnesium administration
|
Systolic blood pressure < 90 or MAP < 65 |
At 1 and 2 hours after magnesium administration
|
|
Incidence of bradycardia
Prazo: At 1 and 2 hours after magnesium administration
|
Heart rate < 60 beats per minute |
At 1 and 2 hours after magnesium administration
|
|
Mean time to achieve goal heart rate
Prazo: at 2 hours
|
Mean time to achieve goal heart rate at 2 hours |
at 2 hours
|
|
Rate of conversion
Prazo: 2 hours after administration of magnesium
|
Rate of conversion to normal sinus rhythm |
2 hours after administration of magnesium
|
|
Clinical need for rescue medication administration
Prazo: 2 hours from metoprolol administration
|
Dose of rescue medications given (magnesium and metoprolol) |
2 hours from metoprolol administration
|
|
Mean change in heart rhythm
Prazo: up to 24 hours after magnesium infusion
|
Mean change in heart rhythm after the administration of magnesium sulfate |
up to 24 hours after magnesium infusion
|
|
Clinical need for rescue medication administration
Prazo: 2 hours from metoprolol administration
|
Route of administration (IV or PO) for rescue medications (magnesium and metoprolol), if administered. |
2 hours from metoprolol administration
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: Marc McDowell, PharmD, Advocate Christ Medical Center Emergency Department
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças cardiovasculares
- Processos Patológicos
- Doenças cardíacas
- Arritmias Cardíacas
- Condições Patológicas, Sinais e Sintomas
- Flutter Atrial
- Compostos de enxofre
- Produtos químicos inorgânicos
- Compostos de cloro
- Ácidos de enxofre
- Compostos de sódio
- Sulfatos
- Ácidos sulfúrico
- Cloretos
- Ácido clorídrico
- Compostos de magnésio
- Sulfato de Magnésio
- Cloreto de sódio
Outros números de identificação do estudo
- IRB00146620
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .